Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Manfidokimab in adolescents with moderate-to-severe atopic dermatitis
NCT06756126Phase 2Not yet recruiting
- Sponsor
- Akeso, Inc.
- Start
- Dec 2024
- Primary completion
- Jun 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of manfidokimab in atopic dermatitis (AD), sponsored by Akeso, Inc.. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
manfidokimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06756126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06756126.